Testing CAR-T cells from patient blood against glioblastoma cells in the lab
Lab study tests immune cells from adults with glioblastoma brain tumors.
Key facts
- Who runs it
- Central Hospital, Nancy, France
- Where
- Vandœuvre-lès-Nancy, FranceSee the site
- Trial code
- Registry title
- Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells in Glioblastoma
- Status
- Not yet recruiting
- People taking part
- 18 people, planned
- Started
- Jan 2025
- Expected to end
- Jan 2027
- Type of study
- Interventional
- Treatments tested
- Blood collection
- Record updated
- 8 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed glioblastoma who have not had any treatment for it yet. Blood is collected for laboratory research.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Glioblastoma confirmed by tissue examination, newly diagnosed (de novo), with non-mutated IDH status (WHO 2021 classification). WHO performance score 0 to 2.
- Earlier treatment
- No earlier treatment for this cancer.
- Biomarker or test result
- Non-mutated IDH status.
Main reasons for not taking part
- Blood cancers, or any other cancer in the past 5 years
- Weak immune system or current immune-suppressing treatment
- Chronic inflammatory disease or a current infection
- Corticosteroids above 10mg/day on the day of blood sampling
- Pregnant or breast-feeding women
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Male or female, adult (age ≥ 18 years)
- WHO 0 to 2
- Patient with a diagnosis of histologically proven de novo glioblastoma with non-mutated IDH status according to WHO 2021 classification
- Patient naïve to any treatment for this cancer
- Patient weighing ≥ 50 kg
- Patient able and willing to follow all study procedures in accordance with the protocol
- Person affiliated to a social security scheme or beneficiary of such a scheme
- Person who has received full information on the organization of the clinical research and has signed an informed consent form
Who cannot take part
- Immunocompromised (with immunodeficiency or current immunosuppressive therapy)
- Anyone taking corticosteroids >10mg/day on the day of blood sampling for research purposes
- People with hematological malignancies
- Chronic inflammatory disease
- Person with current infection
- Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care under articles L. 3212-1 and L. 3213-1
- People with a history of cancer < 5 years old
- Women of childbearing age without effective contraception
- Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public Health Code Pregnant, parturient or breast-feeding women Minor (not emancipated) Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice) Persons of full age who are unable to give their consent
- Anyone with a contraindication to blood sampling
Where in France
- Cell Therapy Unit, Nancy HospitalVandœuvre-lès-Nancy, FranceContact: Loïc REPPEL, PharmD, PhDNo longer taking part
About the trial
What the trial wants to find out
Glioblastoma is a brain tumor with a very poor prognosis, affecting around 2,400 new patients every year. Current treatments do not provide good control of the disease. In view of the therapeutic impasse, it is necessary to develop new strategies. CAR-T cells (Chimeric antigen receptor T cells) represent a highly promising therapy for the treatment of incurable cancers, including glioblastoma. This treatment aims to destroy cancer cells by relying on the patient's own immune system. CAR-T cells are generated from the patient's own immune cells, more specifically T lymphocytes, which are genetically modified to express a tumor-specific receptor on their surface. CAR-T cells bind to tumor cells and cause their destruction. However, these cells have shown limited therapeutic power in the treatment of brain tumors. This is mainly due to the microenvironment surrounding the tumor, which is composed of immunosuppressive cells. These cells, and the molecules they secrete, help to reduce the activity of CAR-T cells that would otherwise reach the tumor. Little is currently known about these resistance mechanisms. The aim of this research is therefore to better understand these resistance mechanisms in order to propose a strategy for enhancing the therapeutic action of CAR-T cells in the treatment of glioblastoma.
Read full original descriptionShow less
The main objective of this research is to evaluate the impact of the tumor environment on the antitumor efficacy of anti-GD2 CAR-T therapeutic cells in an in vitro glioblastoma model. Both tumor environment cells and CAR-T therapeutic cells will be generated from glioblastoma patient cells.
The secondary objectives of this research are to
* Evaluate the impact of tumor environment targeting on the in vitro antitumor efficacy of anti-GD2 CAR-T therapeutic cells. * Evaluate the quality/quantity of generated cells (CAR-T cells and tumor environment cells) in relation to glioblastoma patients. * Evaluate the efficiency of the cell isolation technique (CAR-T cells and tumor environment cells)
The group in the trial
- Blood collection (40 mL) of glioblastoma patientsTreatment being tested
Treatment: Blood collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells Generated From Blood of Glioblastoma Patients
- Plain-language title
- Testing CAR-T cells from patient blood against glioblastoma cells in the labGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 January 2025